Yttrium (90Y) clivatuzumab tetraxetan

Yttrium (90Y) clivatuzumab tetraxetan
Yttrium (90Y) clivatuzumab tetraxetan?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 943976-23-6 N
ATC code None
Chemical data
Formula C6496H9952N1716O2014S44 
Mol. mass 145.7 kDa
 N(what is this?)  (90Y) clivatuzumab tetraxetan (verify)

Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody designed for the treatment of pancreatic cancer.[1] The antibody itself, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

The drug was developed by Immunomedics, Inc.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf. 
  2. ^ WHO Drug Information